This is an open-label, single-arm, phase I/II trial of immune checkpoint inhibitor combined with pemetrexed intrathecal injection for leptomeningeal metastasis from solid tumors.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Recommended dose
Timeframe: From date of treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 6 months.]
Incidence of treatment-related adverse events
Timeframe: From date of treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 6 months.